These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11786751)

  • 41. FDG Accumulation in the Lumen of the Gallbladder Without Related Pathology.
    Bai X; Wang X; Zhuang H
    Clin Nucl Med; 2018 May; 43(5):383-385. PubMed ID: 29485432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract]   [Full Text] [Related]  

  • 44. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 46. Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma.
    Rubello D; Gordien P; Morliere C; Guyot M; Bordenave L; Colletti PM; Hindié E
    Clin Nucl Med; 2015 Aug; 40(8):e405-10. PubMed ID: 26018686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
    Ma LF; Fan W
    Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Muscular FDG uptake after chewing chewing gum in a patient with Hodgkin disease.
    Vock J; Juengling FD; Krause T; Wissmeyer M
    Clin Nucl Med; 2007 Feb; 32(2):124-7. PubMed ID: 17242567
    [No Abstract]   [Full Text] [Related]  

  • 50. Positron emission tomography in the management of lymphomas: a summary.
    O'Doherty MJ; Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S128-30. PubMed ID: 12692689
    [No Abstract]   [Full Text] [Related]  

  • 51. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone involvement in a patient with Hodgkin lymphoma producing granulocyte colony stimulating factor: PET imaging.
    Yoshida T; Sato K; Ozaki K; Matsuyama T; Ozawa K
    Br J Haematol; 2011 Aug; 154(4):424. PubMed ID: 21517819
    [No Abstract]   [Full Text] [Related]  

  • 53. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absorbed 18F-FDG dose to the fetus during early pregnancy.
    Zanotti-Fregonara P; Jan S; Taieb D; Cammilleri S; Trébossen R; Hindié E; Mundler O
    J Nucl Med; 2010 May; 51(5):803-5. PubMed ID: 20395321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin.
    Blodgett TM; Ames JT; Torok FS; McCook BM; Meltzer CC
    Clin Nucl Med; 2004 Mar; 29(3):161-3. PubMed ID: 15162984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDG uptake in liposclerosing myxofibrous tumor causes upstaging of Hodgkin lymphoma.
    Kim J; Chen W; Resnik C; Dilsizian V; Chen Q; Kimball AS
    Clin Nucl Med; 2015 Apr; 40(4):325-7. PubMed ID: 25290293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.